

54. (New) A method of making a terminally methyl-branched iso- or anteiso-fatty acid, or a mixture of said fatty acids, which comprises culturing a bacteria strain containing said fatty acid(s) to form a fermentation solution containing said fatty acid(s), and then isolating said fatty acid(s) from the fermentation solution.

55. (New) The method of claim 54, wherein the culture medium comprises a soybean medium.

56. (New) The method of Claim 54, wherein the soybean medium has the following formula:

Soybean	5-10 %
or soybean milk or bean cake (by soybean wt.)	5-15 %
Yeast extract	0.02-0.5 %
or yeast powder	0.02-0.5 %
CaCO ₃	0.05-0.25 %
K ₂ HPO ₄	0.02-0.10 %
MgSO ₄	0.01-0.05 %
NaCl	0.01-0.04 %
Na ₂ MoO ₄	5.0-30ppm
ZnSO ₄	2.5-15ppm
CoCl ₂	5.0-20ppm.

57. (New) The method of Claim 54, wherein the bacteria strain is from a genus selected from the group consisting of *Stenotrophomonas*, *Xanthomonas*, *Flavobacterium*, *Capnocytophaga*, *Altermonas*, *Cytophage*, *Bacillus*, *Chryseobacterium*, *Empdobacter*, *Aurebacterium*, *Sphingobacterium*, *Staphylococcus*, *Azotobacter* and *Pseudomonas*.

58. (New) The method of Claim 57, wherein the bacterial strain is

Stenotrophomonas maltophilia

59. (New) The method of Claim 58, wherein said bacterial strain is assigned ATCC

202105.

60. (New) A method of making a fermentation solution containing at least one terminally methyl-branched iso- or anteiso-fatty acid, which comprises culturing a bacteria strain containing said fatty acid in a nutritive medium to form a fermentation solution containing said fatty acid.

61. (New) The method of Claim 60, wherein the nutritive medium comprising a soybean medium.

62. (New) The method of Claim 60, wherein the soybean medium has the following formula:

Soybean	5-10 %
or soybean milk or bean cake (by soybean wt.)	5-15 %
Yeast extract	0.02-0.5 %
or yeast powder	0.02-0.5 %
CaCO ₃	0.05-0.25 %
K ₂ HPO ₄	0.02-0.10 %
MgSO ₄	0.01-0.05 %
NaCl	0.01-0.04 %
Na ₂ MoO ₄	5.0-30ppm
ZnSO ₄	2.5-15ppm
CoCl ₂	5.0-20ppm.

63. (New) The method of Claim 60, wherein the bacteria strain is from a genus selected from the group consisting of *Stenotrophomonas*, *Xanthomonas*, *Flavobacterium*, *Capnocytophaga*, *Altermonas*, *Cytophaga*, *Bacillus*, *Chryseobacterium*, *Empdobacter*, *Aureobacterium*, *Sphingobacterium*, *Staphylococcus*, *Azotobacter* and *Pseudomonas*

64. (New) The method of Claim 63, wherein the bacterial strain is *Stenotrophomonas maltophilia*.

65. (New) The method of Claim 64, wherein said bacterial strain is assigned ATCC 202105.

66. (New) A product made by the method of Claim 60.

67. (New) A product made by the method of Claim 61.

68. (New) A product made by the method of Claim 62.

69. (New) A product made by the method of Claim 63.

70. (New) A product made by the method of Claim 64.

71. (New) A product made by the method of Claim 65.

72. (New) A composition comprising an effective amount for preventing cancer, or treating skin disease, or providing an antiaging effect, or providing immune boosting, of at least one terminally methyl-branched iso- or anteiso-fatty acid, or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier, wherein the fatty acid has the formula R_0COOH , wherein R_0 represents a terminally methyl-branched iso or anteiso fatty group.

73. (New) The composition of Claim 72, wherein the composition is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

74. (New) A method of immune boosting comprising administering to a subject in need thereof an effective amount of at least terminally methyl-branched iso- or anteiso-fatty acid, or a pharmaceutically acceptable salt or derivative thereof, wherein the fatty acid has the formula R_0COOH , wherein R_0 represents a terminally methyl-branched iso or anteiso fatty group.

75. (New) A method of prolonging aging comprising administering to a subject in need thereof an antiaging effective amount of at least one terminally methyl-branched iso- or anteiso-fatty acid, or a pharmaceutically acceptable salt or derivative thereof, wherein the fatty acid has the formula R_0COOH , wherein R_0 represents a terminally methyl-branched iso or anteiso fatty group.


76. (New) A method of preventing cancer comprising administering to a subject in need thereof an effective amount of at least one terminally methyl-branched iso- or anteiso-fatty acid, or a pharmaceutically acceptable salt or derivative thereof, wherein the fatty acid has the formula R_0COOH , wherein R_0 represents a terminally methyl-branched iso or anteiso fatty group.

77. (New) The method of Claim 76, where the cancer is skin cancer or mammary cancer.


78. (New) A terminally methyl-branched iso- or anteiso-fatty acid derivative, wherein the fatty acid has the formula R_0COOH , wherein R_0 represents a terminally methyl-branched iso or anteiso fatty group, and wherein said fatty acid derivative has anticancer activity, selected from the following compounds:

(1) R_0CO-A , wherein A represents one of the following groups:


1)




2)




3)




4)




5)




6)




7)




8)




9)




10)




11)



12)



13)



wherein in the above formula 7, R_0' has the same definition as R_0 but may be the same or different, and in the above formula 13, R is a side chain of an amino acid, and n is 0 or an integer;

(3) $R_0\text{CHXCOOH}$ or $R_0\text{CX}_2\text{COOH}$, having more than 8 carbon atoms and wherein X is Cl, I, Br, OH or NH_2 ; and

(4) lipoproteins of said terminally methyl-branched iso- and anteiso- fatty acids, which are obtained by conjugation with a protein.

79. (New) The product of Claim 66, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

80. (New) The product of Claim 67, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

81. (New) The product of Claim 68, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

~~82. (New) The product of Claim 69, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.~~

83. (New) The product of Claim 70, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

84. (New) The product of Claim 71, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

DISCUSSION OF THE AMENDMENT

All the claims have been cancelled and replaced with new Claims 53-84. Claims 53-78 correspond to cancelled Claims 22-42, 47-50 and 52, respectively. Claims 79-84 depend from Claims 66-71, respectively, and includes the limitations of original Claim 42.